The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1656
ISSUE1656
August 8, 2022
Tapinarof Cream (Vtama) for Psoriasis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Tapinarof Cream (Vtama) for Psoriasis
August 8, 2022 (Issue: 1656)
The FDA has approved Vtama (Dermavant), a 1%
cream formulation of the aryl hydrocarbon receptor
(AhR) agonist tapinarof, for treatment of adults with
plaque psoriasis. It is the first AhR agonist to be
approved by the FDA.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.